Effectiveness of Pressure Biofeedback Therapy and Progressive Muscle Relaxation Technique in Improving Pain and Disability Among Patients With Non-Specific Low Back Pain
Launched by DOW UNIVERSITY OF HEALTH SCIENCES · Nov 7, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different treatments for people suffering from non-specific low back pain, which is a common issue affecting many individuals. The trial aims to see how effective a combination of pressure biofeedback therapy—this helps support the lower back by adjusting pressure in the abdomen—and progressive muscle relaxation techniques—designed to reduce tension and improve flexibility—can be in helping patients manage their pain and improve their mobility. The trial is for adults aged 30 to 50 who have been experiencing low back pain for more than three months.
To participate, individuals should be diagnosed with chronic low back pain but should not have had any surgeries on their spine or other serious spine-related conditions. Those who join the trial can expect to receive either the combined treatment or just the muscle relaxation techniques to see which works better for reducing pain and improving their daily activities. This study is actively recruiting participants, and it provides an opportunity for those with chronic back pain to explore new ways to find relief.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosed and referred patients with non-specific low back pain for more than 3 months
- • 30 to 50 years
- • Both genders
- Exclusion Criteria:
- • Any surgical history of lumbar spine
- • Infections of the spine, malignancy
- • Disc protrusion
- • History of spinal fractures
About Dow University Of Health Sciences
Dow University of Health Sciences (DUHS) is a premier educational and research institution based in Karachi, Pakistan, dedicated to advancing healthcare through innovative research and clinical excellence. As a clinical trial sponsor, DUHS integrates cutting-edge scientific inquiry with practical applications, fostering a collaborative environment that promotes the development of new treatments and therapies. The institution is committed to upholding the highest ethical standards in research, ensuring participant safety, and contributing to the global body of medical knowledge. With a focus on interdisciplinary collaboration and community health impact, DUHS plays a pivotal role in enhancing the quality of healthcare both locally and internationally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Karachi, Sindh, Pakistan
Patients applied
Trial Officials
Farhan I Khan, Ph.D, MBA, MSc.PT, DPT
Study Director
Dow University of Health Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials